"Another remarkable vaccine result! There is finally hope rapid mRNA platforms have shown impressive efficacy. Dr. John Moore, the Director of the Duke Human Vaccine Institute and the Center for Vaccine Research, concurred with Pzer's mRNA COVID-19 vaccine is reassuring for the field. We remain hopeful that the other vaccines reported last week, which is a very good indicator that they will be as well.

Michelle Williams, Sc.D., S.M., Dean of the Faculty, Research Council, Research Professor of Pediatrics, and a Vaccine Interventionist, emphasized the need for continued vigilance as these vaccines are developed. It is exciting to think that very soon there will be two vaccines being considered for the entire world. Instead of requiring ultra-cold temperatures, this vaccine can be stored at 2-8°C, making it more accessible.

The updated information Moderna released on stability is really important because as we've seen, individuals over the age of 65 and those in diverse racial/ethnic populations are more likely to die as a result of COVID-19. If there is a consistent level of safety and efficacy among these sub-populations, that would be very positive. John Moore, who is an expert in the field and a summary of Moderna's ongoing Phase III efficacy trial, including the full data, was provided in the press release. The information was presented in a special issue of the Human Vaccines Project, including reactions from several experts in the field.

The Human Vaccines Project (HVP) President and CEO Kristen Jill Abboud discussed these latest results with Wayne Ko, Ph.D., founding member and immediate past president of the HVP.

The HVP has received a grant from the National Institutes of Health to develop a new initiative called the HVP Foundation, which will focus on the development of new vaccines and therapies for infectious diseases that kill large numbers of people. The foundation will be headquartered in New York City and will work closely with universities, hospitals, and government agencies to advance research and develop new treatments for diseases such as COVID-19, malaria, and HIV.

It is a great day for Moderna, for mRNA vaccines, and for the Human Vaccines Project. The continued development of vaccines against COVID-19 is crucial to controlling the pandemic. Now the hard work of vaccination, while retaining essential safe behaviors, begins.

Together, these two announcements show that an mRNA vaccine platform is promising, and that these vaccines may be a vaccine for the elderly, and reduction of viral transmission, but the pandemic. Now the hard work of vaccination, while retaining essential safe behaviors, begins.

Hopefully the good news continues!